Management of patients with immediate reactions to COVID-19 vaccines - 03/02/23
Doi : 10.1016/j.jaci.2022.09.003
Matthieu Picard, MD a, ⁎ 
, Cosby A. Stone, MD, MPH b, Matthew Greenhawt, MD c
, Cosby A. Stone, MD, MPH b, Matthew Greenhawt, MD c a the Division of Allergy and Clinical Immunology, Department of Medicine, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montréal, Québec, Canada
b the Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn
c the Section of Allergy and Immunology, Children’s Hospital Colorado, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colo
∗Corresponding author: Matthieu Picard, MD, FRCPC, Université de Montréal, Division of Clinical Immunology and Allergy, Hôpital Maisonneuve-Rosemont, 5415 Boulevard de l’Assomption, Montréal (Québec), Canada, H1T 2M4.Université de MontréaDivision of Clinical Immunology and AllergyHôpital Maisonneuve-Rosemont5415 Boulevard de l’AssomptionMontréal (Québec)H1T 2M4Canada
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Key words : COVID-19, vaccine, allergy, management, immediate reaction, PEG, vocal cord dysfunction, urticaria, anaphylaxis, ISRR
Le texte complet de cet article est disponible en PDF.
Plan
| Supported by an AAAAI Foundation Faculty Development Award (to C.A.S.). The funders played no role in any aspect of this article. |
|
| Disclosure of potential conflict of interest: M. Greenhawt is a consultant for Aquestive; a member of physician/medical advisory boards for DBV Technologies, Sanofi/Regeneron, Nutricia, Novartis, Aquestive, Allergy Therapeutics, AstraZeneca, ALK-Abelló, and Prota; an unpaid member of the scientific advisory council for the National Peanut Board and medical advisory board of the International Food Protein Induced Enterocolitis Syndrome Association; a member of the Brighton Collaboration Criteria Vaccine Anaphylaxis 2.0 working group; the senior associate editor for the Annals of Allergy, Asthma, and Immunology; and a member of the Joint Taskforce on Allergy Practice Parameters. In addition, M. Greenhawt has received honorarium for lectures from ImSci and MedLearningGroup, and multiple state/local allergy societies. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2022
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 151 - N° 2
P. 413-415 - février 2023 Retour au numéro
Article précédent
- MRGPRX2 in drug allergy: What we know and what we do not know
- Pavel Kolkhir, Hydar Ali, Magda Babina, Didier Ebo, Vito Sabato, Jessy Elst, Stefan Frischbutter, Polina Pyatilova, Marcus Maurer
- Omics-oriented research illustrated with the LEAP study and the OASIS bioinformatics tool
- Carolyn H. Baloh, Kanika Kanchan, Gautam Shankar, Gerald T. Nepom, Rasika A. Mathias, James A. Perry
Bienvenue sur EM-consulte, la référence des professionnels de santé.